logo
Plus   Neg
Share
Email

SoftBank Approves $41 Bln Program To Buyback Shares, Reduce Debt - Quick Facts

SoftBank Group Corp. (SFTBY.PK,SFTBF.PK) announced Monday that its Board of Directors has approved the sale or monetization of up to 4.5 trillion Japanese yen or $41 billion of assets.

The company would repurchase up to 2 trillion yen or $18 billion of its common stock. The balance would be used for debt redemptions, bond buybacks and increase cash reserves. SoftBank plans to execute the transactions over the next four quarters.

The newly authorized program is in addition to the recently announced 500 billion yen share repurchase program.

The monetization of assets represents less than 20 percent of the company's current asset value.

The company at present has more than 27 trillion yen or $245 billion of assets and 1.7 trillion yen or $15 billion of cash on its balance sheet.

SoftBank said the latest actions highlight the Board's confidence in the long-term growth of the business.

The company expects the enhanced share repurchase program and significant debt reductions, including bond buybacks, will further strengthen its balance sheet and enhance its credit rating.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT
>